CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-symptoms-the-true-impact-of-gmg-on-patients-lives/32235/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them m…

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-science-behind-fcrn-antagonists-a-deep-dive-into-their-mechanism-of-action/32241/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but…

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/life-threatening-events-understanding-and-preventing-myasthenic-crisis/32237/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring w…

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-in-mg-their-role-in-diagnosis-and-treatment/32239/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them man…

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-myasthenia-gravis-crafting-personalized-treatment-strategies/32244/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term…

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-fcrn-therapy-addressing-and-reducing-adverse-reactions/32243/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with t…

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/balancing-risk-and-benefit-traditional-mg-treatments-and-medications-to-avoid/32240/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but …

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-gmg-navigating-current-tools-and-approaches/32238/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many de…

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/understanding-disease-progression-the-shift-from-ocular-to-generalized-mg/32236/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but brin…

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fcrn-antagonists-in-myasthenia-gravis-a-new-era-in-targeted-therapy/32242/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with…

CME credits: 0.25 Valid until: 15-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-cycle-addressing-hyperkalemia-in-ckd-and-heart-failure-to-optimize-raasi-therapy/26746/ Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their trea…

CME credits: 0.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/unmasking-igan-from-suspicion-to-timely-diagnosis/26629/ Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addi…

CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-management-practice-trends-and-updates/28868/ The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. Th…

CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-comorbidities-with-pah-and-group-2-ph/28869/ Providers face challenges when it comes to pulmonary hypertension (PH), especially when distinguishing between PAH with comorbidities and group 2 PH. In addition, PH resulting from l…

CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-assessment-in-pulmonary-hypertension-practice-trends-and-updates/28867/ Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their …

CME credits: 0.25 Valid until: 16-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/finally-i-can-take-a-break-from-my-itch-optimizing-ckd-ap-treatment/26639/ Patients with advanced kidney disease undergoing dialysis are frequently affected by the symptom clusters of chronic kidney disease-associated pruritus, or CKD-aP. These sympt…

CME credits: 0.50 Valid until: 13-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/best-practices-for-identifying-diagnosing-and-treating-transthyretin-amyloidosis-attr-pn-and-attr-cm/26799/ Amyloidosis, often unrecognized, misdiagnosed, and either inappropriately treated or undertreated, is a collection of diseases caused by the m…

CME credits: 0.50 Valid until: 13-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-shifting-attr-cm-landscape-early-diagnosis-emerging-therapies-personalized-care/27090/ Achieving optimal outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) remains a challenge as diagnosis is often delayed. Patients have a r…

CME credits: 0.25 Valid until: 13-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-igan-care-from-kidney-week/26628/ In this review of clinical trial results, experts cover the latest data in IgA nephropathy and discuss how their application can improve outcomes for your patients. Studies presented include SPARTAN, SPAR…

CME credits: 0.25 Valid until: 06-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-weight-of-recurrence-navigating-multidisciplinary-care-planning-in-recurringmetastatic-cervical-cancer/29168/ In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals…

CME credits: 1.50 Valid until: 04-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-and-management-of-mash-more-options-more-decisions/24277/ Join us for a CME online broadcast replay of a live satellite symposium from ACG 2024, where experts discuss MASLD/MASH, a serious disease that is both chronic and pr…

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-oncology-learning-center-from-guidelines-to-practice-lung-cancer/29133/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practic…

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-first-line-treatment-of-advanced-nsclc-with-targeted-therapies/29134/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines…

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guidelines-concordant-care-for-advanced-nsclc-with-second-line-targeted-therapies/29136/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guid…

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/application-of-guidelines-recommended-broad-molecular-profiling-to-patients-with-nsclc/29130/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into …

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guidelines-for-immunotherapy-in-the-neoadjuvant-and-adjuvant-settings/29131/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guideli…

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-and-practice-changing-directions-in-nsclc-within-the-perioperative-and-locally-advanced-settings/29137/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncolo…

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guidelines-concordant-immunotherapy-in-the-perioperative-setting-of-nsclc/29132/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines i…

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-optimizing-patient-care-in-nsclc/29139/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical …

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/guidelines-recommended-targeted-therapies-as-second-line-treatment-options-for-patients-with-metastatic-nsclc/29135/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating on…

CME credits: 1.00 Valid until: 27-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-behind-emerging-targeted-therapy-strategies-in-patients-with-metastatic-nsclc/29138/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guideli…

CME credits: 0.25 Valid until: 22-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/fcs-and-shtg-are-we-meeting-need/20306/ Patients with familial chylomicronemia (FCS) and severe hypertriglyceridemia (SHTG) suffer from multiple complications, the most severe being acute pancreatitis. Current therapeutic agents, which include fibrat…

CME credits: 0.25 Valid until: 21-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-igan-novel-therapies-and-evolving-guidelines/26627/ Given that IgA nephropathy is a leading cause of kidney failure, early diagnosis and treatment are essential. In the landscape of the many evolving treatment gui…

CME credits: 0.25 Valid until: 21-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-experiences-in-identifying-and-treating-itch-in-patients-on-hemodialysis/26638/ Patients with chronic kidney disease may be experiencing severe itch, known as CKD-associated pruritus (CKD-aP). Itching and related symptoms, such as reduced sle…

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-is-risky-business/29109/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outc…

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-an-itchy-patient-behind-those-numbers/29113/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of…

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-1/29114/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondria…

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/initiating-second-line-therapy-what-when-and-then-what/29111/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of a…

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-2/29115/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondria…

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/does-your-patient-have-pbc/29108/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies.…

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-a-sleepy-patient-behind-those-numbers/29112/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of…

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-target-practice-normalization-is-the-new-norm/29110/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimi…

CME credits: 0.25 Valid until: 31-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-choices-navigating-early-stage-hr-her2-breast-cancer-with-cdk46-inhibition/26643/ Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiothera…

CME credits: 0.25 Valid until: 23-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/cardiorenal-collaboration-optimizing-multidisciplinary-care-in-the-cvrm-patient/26667/ The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A…

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/going-beyond-todays-assessments-to-confirm-copd-are-biomarkers-key/27035/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the pot…

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-to-pharmaceutical-approaches-in-copd/27036/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biological…

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-copd-from-symptoms-to-assessment-the-2024-gold-standards/27034/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the po…

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/molecular-mechanisms-of-copd/27033/ Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted thera…

CME credits: 0.25 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/unveiling-the-latest-advancements-in-ckd-associated-pruritus-care/26636/ Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disea…

CME credits: 0.50 Valid until: 18-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/new-horizons-unraveling-novel-therapies-for-enhanced-cardiovascular-outcomes-in-patients-with-heart-failure/26966/ There are limited therapeutic options for patients with heart failure with mid-range or preserved ejection fraction (HFmrEF/HFpEF). Rec…